Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.65
Bid: 1.60
Ask: 1.70
Change: 0.00 (0.00%)
Spread: 0.10 (6.25%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.625
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Change of Nomad and Adviser

28 Nov 2008 07:30

RNS Number : 1247J
EpiStem Holdings plc
28 November 2008
 



]

For Immediate Release

28 November 2008

Epistem Holdings plc

 

("Epistem" or "the Company")

Change of Adviser

Amendment to Articles of Association

and 

Notification re Schedule 2 paragraph (g) of the AIM Rules

Epistem (LSE: EHP), the UK biotechnology and contract research company, is pleased to announce the appointment with immediate effect of Piper Jaffray Ltd. as Nominated Adviser and sole broker to the Company. 

The Company announces that following the AGM held on 26th November 2008, the articles of association of the Company were amended by the insertion of the new following article 48:

"Subject always to the provisions of the Companies Act 2006, the board of directors of the Company from time to time may authorise any matter which would, if not so authorised, result in a director infringing his duty under section 175 of the Companies Act 2006 to avoid a situation in which he has, or can have a direct or indirect interest that conflicts or possibly may conflict with the interests of the Company."

All resolutions proposed at the AGM were duly passed.

The Company also announces that Mr. Matthew Walls, the Company's Chief Executive Officer, was previously a director of Zylepsis Limited ("Zylepsis") which went into administrative receivership on 3 October 2003. Mr. Walls gave notice of his resignation from Zylepsis on 10 April 2003 in order to pursue other career opportunities. Having worked an agreed period of notice, Mr. Walls ceased to be an employee of Zylepsis on 10 June 2003, at which date he also ceased to be a director of Zylepsis. The administrative receivership is still ongoing and Mr. Walls has not been the subject of any public criticism in connection with this event.

For further information please contact: 

Epistem

Matthew Walls, Chief Executive Officer

+44 (0) 161 606 7258

Piper Jaffray Ltd.

Neil Mackison / James Steel

+44 (0) 20 3142 8700

De Facto Communications

Anna Dunphy / Mike Wort

+ 44 (0) 20 7861 3838

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
APPDGMZMVNNGRZM
Date   Source Headline
12th May 20207:00 amRNSResults of Broker Option
7th May 20205:25 pmRNSHolding(s) in Company
7th May 20204:58 pmRNSPosting of shareholder circular
7th May 202011:05 amRNSSecond Price Monitoring Extn
7th May 202011:00 amRNSPrice Monitoring Extension
5th May 20206:24 pmRNSResult of Placing
5th May 20209:00 amRNSPrice Monitoring Extension
5th May 20208:50 amRNSProposed Placing and Broker Option
4th May 20205:00 pmRNSWHO Prequalification for Genedrive HCV-ID test
4th May 20202:05 pmRNSSecond Price Monitoring Extn
4th May 20202:00 pmRNSPrice Monitoring Extension
1st May 20202:05 pmRNSSecond Price Monitoring Extn
1st May 20202:01 pmRNSPrice Monitoring Extension
1st May 20207:00 amRNSManufacturing milestones met for SARS-CoV-2 test
29th Apr 20209:06 amRNSSecond Price Monitoring Extn
29th Apr 20209:00 amRNSPrice Monitoring Extension
28th Apr 20204:42 pmRNSSecond Price Monitoring Extn
28th Apr 20204:35 pmRNSPrice Monitoring Extension
28th Apr 20202:05 pmRNSSecond Price Monitoring Extn
28th Apr 20202:00 pmRNSPrice Monitoring Extension
27th Apr 20209:00 amRNSPrice Monitoring Extension
24th Apr 20203:30 pmRNSHolding(s) in Company
24th Apr 20207:00 amRNSDistribution agreement for AIHL test
24th Apr 20207:00 amRNSDistribution agreement for AIHL test
22nd Apr 20207:00 amRNSAppointment of Joint Broker
21st Apr 20204:41 pmRNSSecond Price Monitoring Extn
21st Apr 20204:36 pmRNSPrice Monitoring Extension
21st Apr 20202:52 pmRNSHolding(s) in Company
20th Apr 20209:05 amRNSSecond Price Monitoring Extn
20th Apr 20209:00 amRNSPrice Monitoring Extension
20th Apr 20207:00 amRNSCytiva collaboration on Coronavirus PCR Test
17th Apr 20202:06 pmRNSSecond Price Monitoring Extn
17th Apr 20202:01 pmRNSPrice Monitoring Extension
16th Apr 20202:53 pmRNSHolding(s) in Company
15th Apr 20204:41 pmRNSSecond Price Monitoring Extn
15th Apr 20204:36 pmRNSPrice Monitoring Extension
15th Apr 20202:05 pmRNSSecond Price Monitoring Extn
15th Apr 20202:00 pmRNSPrice Monitoring Extension
15th Apr 202011:05 amRNSSecond Price Monitoring Extn
15th Apr 202011:00 amRNSPrice Monitoring Extension
14th Apr 20209:06 amRNSSecond Price Monitoring Extn
14th Apr 20209:00 amRNSPrice Monitoring Extension
14th Apr 20207:01 amRNSHolding(s) in Company
14th Apr 20207:00 amRNSHolding(s) in Company
31st Mar 202011:52 amRNSHolding(s) in Company
30th Mar 20202:01 pmRNSHolding(s) in Company
30th Mar 202011:06 amRNSSecond Price Monitoring Extn
30th Mar 202011:00 amRNSPrice Monitoring Extension
25th Mar 20207:00 amRNSBusiness Update and SARS-COV-2 tests development
4th Mar 20203:33 pmRNSGrant of options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.